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1. Introduction 
Hematopoiesis is the formation and development of blood cells. In a healthy adult person, 
approximately 1011–1012 new blood cells are produced daily in order to maintain steady state 
levels in the peripheral circulation. Disruption of the steady state may cause the 
development of hematological diseases, such as acute (AML) or chronic myelogenous 
leukemia (CML). All mature blood cells ultimately originate from a rare population of 
primitive pluripotent (multipotential) stem cells. The pluripotent stem cells possess self-
renewal and multi-lineage differentiation potential. The latter process leads to two major 
multipotent progenitors: myeloid progenitors and lymphoid progenitors. The myeloid 
progenitors have the ability to differentiate into mature white cells, erythrocytes, 
megakaryocytes/platelets and mast cells; whereas the lymphoid progenitors cells mainly 
produce mature T, NK, and B lymphocytes. Production of myeloid lineage cells is a highly 
complex process involving the balance between cell proliferation and differentiation, which 
is regulated by growth stimulating or inhibiting signals. Transforming Growth Factor-beta 
(TGFǃ) is a pleiotropic growth factor and is one of the major regulators of hematopoiesis 
(Fortunel NO et al. 2000). A major effect of TGFǃ on hematopoietic cells is inhibitory (Hu X 
et al 1999, Batard P et al. 2000, Ducos K et al. 2000, Fortunel NO 2000) although its 
stimulatory effect has also been observed in some types of blood cells (Keller JR 1990, 1992). 
Due to its importance in the understanding human diseases including leukemia, over past 
20 years, the mechanisms responsible for TGFǃ-induced growth inhibition or stimulation 
have been a major area of investigation and considerable insights into its action mechanisms 
have been learned. This review highlights recent progress in understanding regulatory role 
of TGFǃ and its signaling pathways in various types of cells with a focus on human myeloid 
leukemia cells.  
2. Myeloid leukemia and myelogenous leukemia cell lines 
Myeloid leukemia is a type of blood and bone marrow cancers, which includes AML and 
CML. AML is a characterized by the rapid accumulation of abnormal, immature white blood 
cells in both borrow and blood, which is caused by defects in the progenitors and/or stem cells 
population. Unlike AML, myeloid cell differentiation is preserved during the chronic phase of 
CML, a disease which originates from the presence of a genetic abnormality in stem 
cells/progenitors and the nuclei show an abnormal chromosome called the Philadelphia 
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chromosome. In a healthy person, bone marrow makes the blood stem cells and progenitors 
that mature into mature white blood cells, red blood cells and blood platelets.  
In order to simplify the study of leukemia and basic research, a number of human AML cell 
lines were established. These lines provide model systems to study the control of proliferation 
and differentiation in human myelogenous leukemia and, in a broader framework, the controls 
of normal myeloid development. More than 10 leukemic cell lines have been used in our lab to 
study Transforming Growth Factor-ǃ (TGFǃ)-mediated cell cycle control and transformed 
events, among which K562 is the first myelogenous leukemia cell line established. The cell line 
was isolated from a 53 year old female CML patient in blast crisis (Lozzio CB and Lozzio BB 
1975). K652 composed of undifferentiated blast cells that are rich in glycophorin and may be 
induced to produce fetal and embryonic hemoglobin in the presence of hemin. The rest nine 
cell lines were isolated from AML patients as described below. MV4-11 cell line was derived 
from blast cells of a 10-year-old male with biphenotypic myelomonocytic leukemia (Lange B et 
al. 1987). This cell line expresses mutated FLT3, a member of the type III receptor tyrosine 
kinase (RTK) family (Quentmeier 2003). KG-1 cell line is composed predominantly of 
myeloblasts and promyelocytes ( Koeffler HP et al. 1978). Recent studies identified a fusion of 
two genes encoding fibroblast growth factor receptors, making this cell line is a good model 
for studying gene fusion-linked leukemia (Gu TL et al. 2006). KG-1a ( Koeffler HP et al. 1980) is 
a subline isolated from KG-1. TF-1 is a growth factor-dependent human cell line that was 
originally isolated from the bone marrow cells of a patient with erythroleukemia (Kitamura T 
et al. 1989). TF-1 cells express a wide range of cytokine receptors and respond to a variety of 
cytokines. Thus, this cell line is a useful tool for studying cytokine signaling network (Rosas M 
et al 2005). TF-1a (Hu X et al. 1998) is growth factor-independent subline isolated from TF-1. A 
unique characteristic of the KG-1 and TF-1 cells is their dependence on colony-stimulating 
factor (CSF) or GM-CSF/IL-3 for proliferation, respectively, whereas KG-1a and TF-1a are 
factor-independent cell lines for their growth, although TF-1a retains its ability to respond to 
several growth factors. HL-60 is a promyelocytic cell line derived from peripheral blood 
leukocytes from a female patient with acute promyelocytic leukemia, which can be induced 
into granulocytes in the presence of DMSO (Gallagher R et al.1979). HL-60 cells differentiate 
into mononuclear phagocytes when exposed to phorbol esters (Xu YZ et al. 2011). HEL is an 
erythroleukemia cell line isolated from the bone marrow cells of a patient (Martin P and 
Papayannopoulou 1982). A mutation in Janus kinase 2 gene (JAK2) in HEL cells was identified 
in 2006 (Quentmeier H et al 2006). Mo7e (Avancd GC et al. 1988) is a subline of the M-07 
human megakaryoblastic leukemia cell line. The cells express platelet glycoprotein-2b-3a. The 
growth of Mo7e is dependent on IL-3 or GM-CSF. U937 is a cell line established from a diffuse 
histiocytic lymphoma of 37 year old male patient (Sundstrom C et al. 1976). A histocyte is a cell 
that is part of the mononuclear phagocytic system that takes part in the immune responses. 
Since U937 displays many monocytic characteristics and has thus served as a model for the 
differentiation of monocytes and macrophage in vitro (Aida J, et al. 2011). This cell line is also a 
good model for induction of apoptosis (Piedfer M et al. 2011).  
3. Effect of TGFβ on the growth of human myeloid leukemia cell lines in 
culture  
Transforming Growth Factor-ǃ (TGF) has three isoforms in mammals: TGFǃ1, TGFǃ2, and 
TGFǃ3. The ǃ1 isoform is the most abundant, universally expressed, which has been 
intensively studied. This review focuses on TGFǃ1 unless indicated otherwise. The TGFǃ-
www.intechopen.com
 
Distinct Inhibitory Effect of TGFβ on the Growth of Human Myeloid Leukemia Cells 
 
199 
induced biological activities are achieved through the binding of the ligand to its cell surface 
receptor, a serine-threonine kinase complex, known as type I, II, and III (adaptor) receptors. 
TGFǃ binds to and activates the type II receptor. Then the type II receptor recruits and 
phosphorylates the type I receptor, which in turn activates Smad family proteins that carry 
signals from the receptors to the nucleus to control transcription of target genes. These gene 
products may stimulate or inhibit cell cycle progression. TGF plays an essential regulatory 
role in the control of hematopoiesis (Fortunel NO et al. 2000). First, the development of 
hematopoietic cells from mesoderm in embryos is regulated by TGFǃ signaling. Park et al 
(Park C et al. 2004) demonstrated that BMP-4, a member of TGFǃ superfamily, is able to 
induce hematopoietic differentiation from mouse embryonic stem cells. The differentiated 
cells contain all types of myeloid and lymphoid progeny (Olsen AL et al. 2006). Similar roles 
of TGFǃ in human hematopoietic stem cells have been reported (Kaufman DS  et al. 2001, 
Chadwick K et al. 2003, Cerdan C et al. 2004). Second, it has also been found that TGF is 
required for maintaining hematopoietic stem/progenitor cells in quiescent states (Batard P 
et al. 2000); in contrast, application of anti-endogenous TGF antibody induces release of 
these cells from G1 phase (Ducos K et al. 2000). In TGFǃ-/- mice, enhanced numbers of 
circulating granulocytes, monocytes, platelets, as well as colony forming units, were 
observed (Kulkarni AB et al 1993, Shull MM et al 1992). In addition, inactivation of the TGF 
signaling pathway leads to malignant transformation of early hematopoietic cells (Le 
Bousse-Kerdiles MC et al. 1996). These data indicate that TGFǃ is inhibitory to 
hematopoietic cells. However, studies from several groups suggest that the response of 
myeloid stem/progenitor cells to the inhibitory effect of TGFǃ appears to be inversely 
correlated with their maturation stage (Sing GK 1988, Keller JR 1990, Ottmann OG & Pellus 
LM 1991, Snoeck H-W 1996). Long-term repopulating stem cells, CD34+ or CD34+/CD38- 
stem/progenitor cells, early myeloid and erythroid progenitors are markedly inhibited in 
the presence of TGF, whereas more differentiated myeloid progenitors forming 
granulocyte-macrophage colonies, and late erythroid progenitors forming CFU-e are less 
inhibited or even stimulated by TGF (Keller JR 1990, 1992, 1994, Fortunel NO 2000, Ruscetti 
FW 2005, Sitnicka E 1996, McNiece IK 1992, Goey H 1989, Morita N 2003, Classen S 2007). 
The inhibitory or stimulatory role by TGFǃ in some cases seems to correlate with the 
cytokines used to promote cell growth. TGFǃ inhibits SCF-, IL-3- and CSF-1-induced colony 
formation from mouse and human hematopoietic progenitors (McNiece IK 1992, Sitnicka E 
et al 1996). In contrast, TGFǃ enhances GM-CSF-induced colony formation derived from 
normal bone marrow cells and Lin- progenitors (Keller JR 1991).  
For leukemia cells, both inhibitory and stimulatory effects have been reported (Tessier N & 
Hoang T 1988, Otten J 2011, Aglietta M 1989, Cashman JD 1992). TGF has been shown to 
inhibit the growth of clonogenic blast cells from patients with acute myeloblastic leukemia 
(AML) (Tessier N & Hoang T 1988). Mutations in the components of TGFǃ signal pathways 
may relate to the disease development (Imai Y et al. 2001). In contrast, high expression of 
ALK-1 and ALK-5, two members of TGFǃ type I receptors, was reported to be associated 
with AML (Otten J 2011). An inhibitory effect of TGFǃ was suggested by the finding of low 
levels of TGFǃ type II receptors in CML (Rooke HM 1999) and lymphoid neoplasms (Inman 
GJ et al 2000); whereas, by using TGFǃ inhibitors, Naka et al found that TGFǃ signal is 
required for maintaining Leukemia Initiating Cells (LIC) by controlling nuclear localization 
of transcription factor, FOXO, in a CML mouse model (Naka K et al. 2010).  
The data described above suggest that TGF has both negative and positive effects on the 
proliferation of normal hematopoietic and leukemia cells. However, some of the data appear 
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discordant, which may be due to the complexity of the network in vivo. In the presence of 
other growth factors, TGF-induced stimulation or inhibition could be an indirect result or 
affected by other factors. Therefore, using a cell line as a research model may provide a 
direct effect of TGFǃ and produce more consistent results. A TGF knock out hematopoietic 
cell line exhibited increased colony formation in response to IL-3, IL-6, and G-CSF (Kim S-J 
& Letterio J 2003), suggesting that TGFǃ is inhibitory to the cells. TGF has been reported to 
inhibit proliferation of mouse myeloid leukemic M1 cells and induce adherence of M1 
myeloid leukemia cells to plastic dishes (Okabe-Kado J 1989). In Josk-1 monoblastic 
leukemia cells, dephosphorylation of pRb and inhibition of c-myc were responsible for 
TGF1-induced G1 arrest (Furukawa Y 1992). In U937 cells, it identified that the inhibition 
of the cells by TGF1 was linked to low levels of transcription factors, C-jun, C-fos and Jun B 
(Kanatni Y 1996). In order to delineate the effect of TGF on more myeloid leukemia cell 
lines and to reach a general conclusion, we examined more than 10 human myeloid 
leukemia cell lines, among which MV4-11 and TF-1a are factor-independent but response 
cell lines; TF-1 and Mo7e are factor-dependent cell lines; and KG-1, KG-1a, K562, U937, 
HL60, and HEL are factor-independent and insensitive to any growth factors. We 
demonstrated that TGF is inhibitory for all these human myeloid leukemia cell lines in 
culture, with heterogeneous inhibitory responses being observed (Hu X et al 1999, Hu X & 
Zuckerman KS 2000). Inhibition of TF-1, KG-1, and K562, Mo7e, and HEL by TGFǃ has also 
been reported by other groups recently (Moller GM et al. 2007, Koutoulaki A et al 2010, 
Fukuchi Y et al 2001, Kalina U et al. 2001). Our data and some recent discoveries, clearly 
indicate that the responses of the cell lines to TGFǃ are not related to the apparent 
differentiation stages of the cells (Hu X et al 1999) but could result from differences in the 
amount of TGF receptors expressed or the degrees of the mutations (Quentmeier et al. 
2003, 2006, Gu TL et al. 2006) in TGFǃ signal components in these cells. The mechanisms by 
which TGFǃ inhibits hematopoietic cells involves in the regulation of pRb pocket proteins-
E2F complexes, downregulation of a number of cell cycle regulatory molecules, and 
upregulation of p21 (Ducos K et al 2000) and p57 (Scandura JM et al 2004) as described in 
following sections.  
4. Regulation of pRb-E2F complexes in human myeloid leukemia cells 
pRb acts as a signal transducer collecting signals from cell cycle regulatory molecules to 
transcriptional machinery. G1 protein kinases have been reported to modify pRb by 
phosphorylation, thereby promoting cell cycle progression toward DNA replication 
(Suryadinata R et al. 2011, Takaki T et al. 2004). The growth inhibition of human myeloid 
leukemia cells by TGFǃ is linked to suppression of pRb phosphorylation on multiple serine 
and threonine residues, including Ser249/Thr252, Thr373, Ser780, Ser795, and Ser807/811 
(Chen P et al. 1989, Mihara K et al. 1989, Hu X et al. 1999). Dephosphorylated pRb interacts 
with E2F transcription factors. E2F-binding sites have been found in the promoters of many 
genes that control cell cycle progression and cell proliferation, thereby E2Fs play a critical 
role in cell growth control (Iaquinta PJ et al. 2007). Previous studies identified that E2F binds 
to the pocket domain of pRB. In E2F1, the pRB-binding domain interacts with the C-
terminus of the E2F molecule. As a consequence of the pRB-E2F interaction, E2F activity is 
repressed. pRB, therefore, exerts its growth suppression function mainly through its 
sequestration of E2F activity. However, one recent report suggests that E2F-1 binding 
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affinity for pRb is not the only determinant of the E2F1 activity (Sahin F and Sladek TL 
2010a). Of the seven E2Fs well documented, E2F1, E2F2, and E2F3 are considered as 
“activator” E2Fs, whereas, E2F4, E2F5, E2F6, and E2F7 are considered to be “repressor” E2Fs 
(Attwooll C et al. 2004, Sahin F and Sladek TL 2010b). pRb and two pRb-related proteins, 
p107 and p130, show a common structure, which are collectively termed the “pocket 
proteins”. E2F1-3 bind to pRb, and E2F5 binds to p130. E2F4 can interact with the all three 
pocket proteins.  
Dephosphorylated pRb preferentially interacts with E2F1-3 (Weinberg RA et al. 1995), and 
the pRb/E2F complexes are found primarily during the G1 phase of the cell cycle (Shirodkar 
S et al. 1992, Schwarz JK et al. 1993), during which time E2F-responsive promoters are 
repressed. The dissociation of the pRb/E2F-repressor complex and liberation of free E2F 
allows for the activation of these promoters (Hiebert SW et al. 1993, Qin X-Q et al. 1995, 
Helin K et al. 1993). It was demonstrated that E2F-1 responsive gene activation was 
inhibited by overexpression of wild-type pRb, but not by a mutant pRb, whereas 
transactivation mediated by mutants of E2F1, which do not bind to pRb, was not affected by 
overexpression of wild-type pRb. Loss of E2F1-3 resulted in an acute cell cycle arrest (Wu L 
et al. 2001). It has been found that Rb gene was often mutated in patients with various 
cancers, whereas p107 and p130 genes appear to be less frequently mutated in human 
cancers, suggesting that pRb is a tumor suppressor, whereas p107 and p130 are not. 
However, recent studies from several labs have shown that p130 and p107 also actively 
involved in E2F-dependent transcription activities. For example, the major E2F complexes in 
quiescent fibroblasts were E2F4-p130. As cells enter the cell cycle, E2F4-p130 was replaced 
by E2F4-p107 and E2F4-pRb (Ikeda M et al. 1996, Moberg K et al. 1996). Subsequent 
investigators, by performing chromatin immunoprecipitation (ChIP) experiments, were able 
to locate E2F complexes in a gene promoter. They have demonstrated that in serum-
deprived cells, predominantly E2F4, p130, and a histone deacetylase (HDAC) are found to 
bind to corresponding E2F-responsive promoters (Rayman JB et al. 2002, Ren B et al. 2002, 
Takahashi Y et al. 2000). Since histones are generally hypoacetylated when a gene is turned 
off, which is regulated by HDAC, the results described above suggest that p130-E2F4 DNA 
binding activity is required for the gene inactivity and for arresting cells in quiescent state. 
As cells progress through mid-G1, E2F4 and p130 are replaced by activators E2F1, 2, and 3. 
Unexpectedly, loss of pRB had no effect on HDAC recruitment to the promoter or pRb was 
not detectable in the promoters containing the E2F responsive site in quiescent cells 
(Rayman JB et al. 2002, Takahashi Y et al. 2000). Thus, these data suggest that pRb may not 
be a primary negative regulator of E2F activity in control of cell cycle progression in these 
cells.  
As indicated in the previous section, TGF dramatically inhibits the growth of several 
human myeloid leukemia cell lines in culture with a maximal growth inhibition being 
observed in MV4-11 cells. We asked how pRb-E2F complexes were regulated in MV4-11 
cells. We found that in actively proliferating MV4-11 cells, p130 and pRb were expressed as 
peptides that migrated in multiple bands in SDS-PAGE, whereas in the cells treated with 
TGFǃ, p130 and pRb were dephosphorylated. However, TGFǃ did not dephosphrylate p107 
but inhibited expression of the molecule (Hu X et al. 2000). Subsequently, we found that 
TGFǃ-treated MV4-11 cells had very low levels of pRb-associated E2F1 and E2F3. The low 
levels of pRb-E2Fs are resulted from a low expression of E2F1 and E2F3 in response to TGF 
that arrested cells in G1 phase. Unexpectedly, proliferating cells without TGFǃ contained 
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substantial quantities of pRb-E2F1 and pRb-E2F3 complexes. In contrast, the cells treated 
with TGFǃ (i.e. G1 cells) showed increased levels of pRb-E2F4 and p130-E2F4 and low level 
of p107-E2F4, as detected by immunoprecipitation and Western blotting. Since TGFǃ 
treatment inhibited the expression p107 but not E2F4, thus, the low level of p107-E2F4 
complexes is a result of the inhibition of p107. Our data indicate that E2F4 was switched 
from p107 to pRb and p130 when p107 was inhibited in response to TGF treatment. By 
performing electrophoretic gel mobility shift assay (EMSA), we were not able to detect pRb-
E2F4 DNA binding activities either in proliferating cells or in G1 cells but exhibited the 
existence of p107-E2F4 and p130-E2F4 DNA binding complexes in G1 cells. which is 
consistent with the reports from the ChIP experiments described above. Taking together, 
our data suggest that p107 and p130, but not pRb, and the repressor E2F, but not activator 
E2Fs, play a critical role in regulating E2F-responsive gene expression in TGFǃ-mediated 
cell cycle control in human myeloid leukemia cells. This conclusion is consistent with 
several studies that have failed to detect pRb at E2F-responsive genes, whereas p107 and 
p130 are readily detectable (Aslanian A 2004, Rayman JB 2002, Takahashi Y 2000, Wells J 
2000). In addition, many cell cycle-regulated E2F targets are depressed in p107-/- and p130-
/- cells but are not depressed in Rb-/- cells (Herrera RE 1996, Hurford  Jr RK 1997, Mulligan 
GJ 1998). It is not clear if traditional activator E2Fs have any significant impact on cell cycle 
progression of MV4-11 cells, because pRb-E2F1 and pRb-E2F3 complexes have been found 
in the proliferating but not in G1 phase cells. Previous studies suggest that pRb may bind 
other regulatory regions of DNA or uses other mechanisms (Sun H et al. 2011), directly or 
indirectly, for its inhibitory function as a tumor repressor. pRb may also have both positive 
or negative role on cell growth, depending on the transcription factors it interacted (Calo E 
et al. 2010).  
5. TGFβ inhibits both G1 and G2 protein kinases in human myeloid leukemia 
cells 
In mammalian cells, the cell cycle progression is regulated by a group of cyclin dependent 
kinases (cdks) and their regulatory subunits in sequential order: cyclin D-cdk4/cdk6 and 
cyclin E-cdk2 complexes act on G1 and G1-S transition, respectively, followed by cyclin A-
cdk2 on S and cyclin B-cdc2 at G2-M transition. TGF is well known to be a negative 
regulator of G1 cyclin/cdk activity in many types of cells. This has been reported to be a 
major mechanism that is responsible for TGF-induced growth inhibition of cells. In 
epithelial and fibroblasts, the negative role of TGFǃ includes inhibition of cdk4 and 
disruption of cyclin E-cdk2 assembly (Ewen ME et al. 1993, Koff A et al 1993). Although 
TGFǃ is known to be a G1 cdk inhibitor, studies from several groups suggest potential effect 
of TGFǃ on G2 checkpoint kinase. For instance, the mouse epithelial cells treated with TGFǃ 
expressed a lower level of cdc2 as compared with the cells without TGFǃ ( Fautsch MP et al 
1995); in a hepatoma cell line, TGFǃ activates cdc2 and cdk2 followed by phosphorylation of 
pRb which in turn triggers apoptosis of the cells (Choi KS et al 1999). A new report 
published in 2008 presented evidence that disruption of Smad 3, a key component of TGFǃ-
induced signal pathway, elevated cdk 1(cdc2) activity via upregulating the expression of 
cyclin B. As a result, the uncontrolled cdk1 delayed mitotic progression (Fujita T 2008). In 
human myeloid leukemia cells, we found that inhibition of multiple cdks including cdc2 
and cdc25C is a dominant event in TGFǃ-induced growth inhibition of the cells (Hu X et al. 
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2001). Our recent studies, using TF-1 and MV4-11 human myeloid leukemia cells, 
demonstrated that TGF1-induced inhibition of leukemia cell growth is not due solely to 
downregulation of G1 cyclins and cdks but also G2 check point kinases (Hu X 2007). In MV4-
11 cells, TGF caused a rapid and transient dephosphorylation of cdc2 (Tyr15) and cdc25c 
(Ser216), with 60% and 70% inhibition of phosphorylation of the both proteins by 2-3 hours, 
respectively, followed by returning to near normal by 12 hours, and 70-100% inhibitions 
again by 24-72 hours, repectively. The dephosphorylation of cdc2 and cdc25c was followed 
by a dramatic decrease of total cdc25c (100% decrease at 48 and 72 hours) and cylcin B1 and 
cdc2 (70-90% reduction at 24 to 72 hours). Consistent with these data, cdc2 kinase activity, as 
determined by ability to phosphorylate histone H1 and GST-Rb in vitro, was markedly 
reduced in the leukemia cells treated with TGF for 24-48 h. Cyclin B1 and cdc25c were 
degraded in a ubiquitin/26S proteosome assay system in vitro, which suggests strongly that 
ubiquitination and proteasomal degradation may be the key mechanism of degradation that 
leads to block of G2-M transition. The downregulation of cdc2, cdc25c, and cyclin B1 was not 
a result of G1 arrest but a direct effect of TGFǃ, because the time required for the inhibition 
of the cells released from G2 is much shorter than the cells released from G1. Using 
immunoprecipitation and Western blotting we detected that the levels of cyclin B1-cdc2 
complexes were much lower in extracts of TGF-treated cells than in control cells. Based on 
our data, we suggest that TGFǃ suppresses growth of human myeloid leukemia cells 
through multiple pathways, by inhibiting both G1 and G2 checkpoint kinases. Since the G1 
and G2 checkpoint kinases are able to phosphorylate pRb in proliferating cells, the down 
regulation of G1 and G2 checkpoint kinases would prevent pRb phospharylation, leading to 
G1 arrest. The data also suggest that cdc2, a traditional G2 regulator in mammalian cells, 
may participate in G1 regulation. Fig. 1 illustrates diagrammatically the negative roles of 
TGFǃ in the cell cycle control in myeloid leukemic MV4-11 cells.  
 
 
Fig. 1. TGFǃ inhibits both G! and G@ cdks in MV4-11 cells 
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6. Dual roles of cdk inhibitors in human myeloid leukemia cells 
It is well known that activity of cdks is counterbalanced by cdk inhibitors (ckis). The cdk 
inhibitors can be classified into two different families: Ink4 (p16, p15, p18 and p19) and 
cip/kip (p21, p27, and p57), based on their structure similarity. Among these cdk inhibitors, 
p27 and p21 have been intensively studied in various types of cells. In quiescent cells or cells 
treated with TGFǃ show high level of p27, whereas proliferating cells or cells treated with 
mitogens express low level of p27 (Moller MB 2000). Overexpression of p27 in cultured cells 
arrests the cells in G1 phase and antisense inhibition of p27 reverses cell cycle arrest induced 
by p27 (Coats S et al 1996; Rivard N et al. 1996). In vivo, p27 is a critical regulator of cellular 
proliferation. Mice lacking p27 gene are 15–30% larger than their wild-type or hemizygous 
(p27+/−) littermates (Fero et al. 1996; Kiyokawa et al. 1996). p27 was initially thought to 
interfere with the activities of cyclin D-, E-, and A-dependent kinases. The crystal structure 
of p27 bound to cyclin-cdk2 reveals that a p27 fragment inserts itself within the cdk2 
catalytic site, blocking ATP access (Russo et al., 1996). These data lead to a popular model in 
which anti-proliferative stimuli up-regulate p27, followed by inhibition of cyclinD-cdk4, 
cyclinE-cdk2, cyclin A-cdk2 activities, and by G1 arrest/growth inhibition. Similar to p27, as 
a negative regulator of the cell cycle progression, p21 is thought to bind and inhibit 
cdk2/cyclin E and/or cdk4/cyclin D complexes, thereby arresting cells at the G1 phase. The 
induction of p21 is regulated by the tumor suppressor gene, p53, in response to DNA 
damage.  
The traditional model of p27 or p21 as a cdk inhibitor has been challenged by a number of 
studies from several labs in which p21 or p27 were demonstrated to be required for a 
cdk/cyclin kinase activity or to be a dual player in cell cycle control (Zhang H et al 1994, 
LaBaer et al 1997). It was reported that p21, at low concentration, promotes the assembly of 
active kinase complexes, whereas a high concentration of p21 causes the opposite effect in 
SAOS-2 cells derived from osteosarcoma (LaBaer et al., 1997). In an animal model, it was 
found that low concentration of p21 could promote tumor progression in the presence of 
oncogenic factors (Jones JM 1999). Primary mouse fibroblasts that are p21-/- and p27-/- 
were failed to assemble cylcin D-CDK complexes and were unable to direct cyclin D nuclear 
translocation (Cheng M 1999). Consistent with this report, p27 was demonstrated to be 
essential for mouse mammary gland morphogenesis and function (Muraoka RS et al. 2001); 
an increased level of p21 was found to be parallel with S-phase entry of oligodendrocytes 
(Bansal R et al. 2005). In another report published in the same year, p27 in mouse T cells was 
found to acts as a promoter during the early stage of the cell cycle (Rowell EA et al 2005). In 
addition, it has been reported that in MCF-7 cells, cyclin D1 promotes cellular migration 
through inducing the expression of p27 and by physically associating with p27 to promote 
cellular migration (Li Z et al. 2006). These dual roles of p21 and p27 in non-hematopoietic 
cells are consistent with what we found in human hematopoietic cells a few years ago. By 
using several human myeloid leukemia cell lines as research models, we demonstrated that 
p27 has differential effect on cdk2 and cyclin E activities, which provides supplementary 
information to the evidence of p27 and p21 having dual roles in cell cycle control described 
above (Hu X et al. 2001). Although TGFǃ greatly upregulated p27 in both cytosol and 
nucleus in MV4-11 cells, the association of p27 with cylcin E and cdk2 showed different 
patterns with increased amount of cyclin E-p27 and decreased levels of cdk2-p27 being 
detected by Western blot and immunoprecipitation. Surprised, a significant amount of p27 
was found to associate with cdk2 in proliferating cells, which was downregulated in 
www.intechopen.com
 
Distinct Inhibitory Effect of TGFβ on the Growth of Human Myeloid Leukemia Cells 
 
205 
response to TGFǃ. The downregulation is a result of inhibition of total cdk2 by TGFǃ. 
However, TGF had no effect on the expression of cyclin E. By carrying out p27 
immunodepletion and transfection experiments, we further demonstrated that that at least 
some cdk2 kinase activity is associated with p27 in MV4-11cells. Additional support for this 
possibility was the observation that cells transfected with anti-sense p27 cDNA but not 
empty plasmid, downregulated cdk2 kinase activity by more than 60%. Although p27 also 
may act as an adapter of cyclin E activity, as suggested by expression of cyclin E- p27 
complexes in proliferating MV4-11 cells, p27 mainly acts as an inhibitor of cyclin E activity 
in response to TGF. This is indicated by the fact that TGF1 upregulated cyclin E-
associated p27 and was accompanied by the inhibition of cyclin E-dependent kinase activity. 
Moreover, p27 immunodepletion dramatically upregulated cyclin E-dependent kinase 
activity in TGF1 treated cells. The effect of p27 on cyclin E-dependent kinase activity is 
dose-dependent, with only high concentrations of p27 being inhibitory to cyclin E activity. 
This may explain the observation that immunodepletion of p27 or anti-sense p27 cDNA did 
not significantly increase cyclin E-dependent kinase activity in proliferating MV4-11 cells. 
These results are against the notion that p27 is a negative regulator of cdk2 kinase in vivo, at 
least in these human myeloid leukemia cells. Our data are consistent with previous findings, 
in which cell cycle arrest mediated by TGF remained intact in p27-/- cells (Nakayama et 
al., 1996) and p21 and p27 has dual roles in cell cycle control (Rowell EA et al. 2005, LaBaer 
et al. 1997, Zhang H et al. 1994). The difference is that the negative or positive role of p27 in 
our model is related to the molecules p27 interacted but not the concentrations of p27 as 
reported in the case of p21 (Matsushime et al., 1992). Taken together, we interpret our 
results to suggest that in proliferating cells p27 is associated with cdk2 and cdk4 as an 
adapter. TGF1 downregulates cdk2, cdk4, and D-type cyclins, which leaves p27kip1 free to 
bind and saturate cyclin E, inhibiting cyclin E-cdk2 assembly, rendering cyclin E-dependent 
kinase inactive. By using these two different regulatory mechanisms, TGF1 magnifies its 
cell cycle inhibitory efficiency in human myeloid leukemia cells (Hu X et al 2001).  
7. Conclusion  
New findings in recent years have provided insight into the complex roles and action 
mechanisms of TGFǃ in various types of cells. TGFǃ exhibits its distinct effect on the growth 
of human myeloid leukemia cells. Although both positive and negative roles of TGFǃ in 
hematopoiesis have been reported, the major role of TGFǃ appears to be inhibitory with 
heterogeneous responses being observed in human myeloid leukemia cells. The 
heterogeneous responses of the cells to TGFǃ are not related to the apparent differentiation 
stages of the cells but could result from differences in the expression of TGF receptors or 
degrees of the mutations in the components of TGFǃ signal pathways. TGFǃ, a traditional 
G1 cdk inhibitor, represses not only G1 but also G2 protein kinases in human myeloid 
leukemia cells. pRb has been reported to be a tumor suppressor in various types of cells. The 
new studies suggest that p130, whose gene is less mutated in cancer patients, plays a critical 
role in maintaining cells in quiescent status and in TGFǃ-mediated growth inhibition. 
Traditionally, p27 and p21 are G1 cdk inhibitors. However, new evidence suggests that p27 
and p21 have both positive and negative effect on G1 cdk activities.  
Based on the data described in this review, it is clear that TGFǃ signals have a defined role 
in regulating normal hematopoiesis, and disruption of the signaling components could lead 
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to hematologic malignancies including myeloid leukemia. These are suggested by the 
observations described above: (1) The development of hematopoietic cells from mesoderm 
in embryos is regulated by TGFǃ signaling; (2) inactivation of the TGF signaling pathway 
leads to malignant transformation of early hematopoietic cells; (3) abnormal expressions of 
the components of TGF signaling pathway have been found in AML and CML; and (4) a 
number of mutations of genes that encode TGFǃ signaling components have been detected 
in several myeloid leukemia cell lines. Thus, the mutated components may be the targets for 
therapeutic strategy of myeloid leukemia in future.  
Although new information on TGFǃ and myeloid leukemia have been emerged at an 
incredibly rapid pace, it is unclear whether some information obtained from studies 
performed in vitro mimic a physiological status in vivo. In addition, the detail about dual role 
of cdk inhibitiors and the role of pRb in leukemia transformation are also need to be 
clarified in future.  
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